Abiopharma

(30% Negative) Dyne Therapeutics, Inc. (DYN) Reports Q3 2022 Financial Results

(19% Negative) ADAPTIMMUNE THERAPEUTICS PLC (ADAP) Reports Q3 2022 Financial Results

(90% Positive) Royalty Pharma plc (RPRX) Reports Q3 2022 Financial Results

(10% Negative) INSMED INCORPORATED (INSM) Reports Q3 2022 Financial Results

(10% Negative) Compugen Ltd (CGEN) Announces 2022 Annual General Meeting

(99% Neutral) Compugen Ltd (CGEN) Files Form 6-K

(30% Negative) ProQR Therapeutics (PRQR) Reports Q2 2022 Financial Results (Form 6-K)

(10% Negative) PROVENTION BIO, INC. (PRVB) Announces Delay in results Trials for support of its ongoing review Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

(30% Negative) Agios Pharmaceuticals, Inc. (AGIO) Reports Q3 2022 Financial Results

(10% Negative) JOUNCE THERAPEUTICS, INC. (JNCE) Announces Delay in results Trials for December Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment